Cancer immunotherapy: unique perspectives for endocrine-related cancers

    1. Laura S Ward5
    1. 1Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore, Singapore
    2. 2Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
    3. 3Oncology Academic Clinical Program, SingHealth Duke NUS Medical School, Singapore, Singapore
    4. 4Institute of Cellular and Molecular Biology, Agency for Science, Technology and Research, Singapore, Singapore
    5. 5Laboratory of Cancer Molecular Genetics, Faculty of Medical Sciences, University of Campinas (FCM-Unicamp), Rua Tessalia Vieira de Camargo 126, Barao Geraldo, Campinas, Sao Paulo, Brazil
    1. Correspondence should be addressed to J Ngeow or L S Ward; Email: joanne.ngeow.y.y{at} or ward{at}

    The landscape of therapeutic options for patients with cancer has changed dramatically in the last decade. Advances in understanding the role of driver mutations in mediating tumor growth and progression, coupled with the development of molecular inhibitors for defined mutations, have given rise to precision oncology. Parallel to this development, significant progress in tumor immunotherapy has resulted in several new strategies for cancer therapy. Effective tumor immunotherapy strategies are designed to promote the cancer-immunity cycle and block the immune-suppressive effects of established tumors. Approaches have included checkpoint inhibitors that prevent T-cell unresponsiveness, toll-like receptor agonists, oncolytic viruses that induce necrotic tumor cell death and trigger systemic antitumor immunity and adoptive transfer of native and genetically engineered T cells that are designed to recognize specific tumor antigens through the T-cell receptor. The practicing oncologists and scientists will need to understand these developments intimately if they wish to take advantage of these therapeutic options.

    In this special issue of Endocrine-Related Cancer, we intentionally highlight some of the unique perspectives related to the use of cancer immunotherapy in endocrine-related cancers. Lucas Leite Cunha and …

    | Table of Contents